You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameVasopressin
Accession NumberDB00067  (BTD00110, BIOD00110)
TypeBiotech
GroupsApproved
DescriptionAntidiuretic hormone, also known as vasopressin, is a nine amino acid peptide secreted from the posterior pituitary. Antidiuretic hormone binds to receptors in the distal or collecting tubules of the kidney and promotes reabsorbtion of water back into the circulation
Protein structureNo structure small
Related Articles
Protein chemical formulaC46H65N15O12S2
Protein average weight1084.23 Da
Sequences
>DE = Vasopressin
CYFQNCPRG
Download FASTA Format
Synonyms
8-Arginine vasopressin
8-L-arginine vasopressin
ADH
Antidiuretic hormone
Arginine vasopressin
Argipressin
AVP
Vasopressin, unspecified
External IDs Not Available
Product Ingredients
IngredientUNIICASInChI KeyDetails
Vasopressin tannate4R069M4O1P Not AvailableNot applicableDetails
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Pitressin Inj 10 Unit/0.5mlLiquid10 unitIntramuscular; SubcutaneousParke Davis Division, Warner Lambert Canada Inc.1971-12-311997-08-25Canada
Pressyn ArLiquid20 unitIntramuscular; SubcutaneousFerring Pharmaceuticals2002-11-042017-03-10Canada
Vasopressin Inj 20unit/ml USPLiquid20 unitIntramuscular; Nasal; SubcutaneousFerring Pharmaceuticals1988-12-312015-07-22Canada
Vasopressin Inj 20unit/ml USPLiquid20 unitIntramuscular; SubcutaneousLyphomed, Division Of Fujisawa Canada Inc.1992-12-311996-09-10Canada
Vasopressin InjectionSolution20 unitIntramuscular; SubcutaneousFresenius Kabi1996-08-14Not applicableCanada
Vasopressin Injection USPSolution20 unitIntramuscular; SubcutaneousSandoz Canada Incorporated2003-12-10Not applicableCanada
VasostrictInjection20 [USP'U]/mLIntravenousPar Pharmaceutical2014-11-12Not applicableUs
VasostrictInjection20 [USP'U]/mLIntravenousPar Pharmaceutical2017-02-27Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PitressinInjection20 [USP'U]/mLIntramuscular; SubcutaneousCardinal Health2007-10-01Not applicableUs
PitressinInjection20 [USP'U]/mLIntramuscular; SubcutaneousPar Pharmaceutical2007-10-012016-06-30Us
VasopressinInjection20 [USP'U]/mLIntramuscularCardinal Health2011-10-17Not applicableUs
VasopressinInjection, solution20 [USP'U]/mLIntramuscular; SubcutaneousGeneral Injectables & Vaccines2013-12-17Not applicableUs
VasopressinInjection, solution20 [USP'U]/mLIntramuscular; SubcutaneousFresenius Kabi2001-07-17Not applicableUs
VasopressinInjection, solution20 [USP'U]/mLIntramuscular; SubcutaneousAmerican Regent1996-08-15Not applicableUs
VasopressinInjection, solution20 [USP'U]/mLIntramuscular; SubcutaneousAmerican Regent1992-10-01Not applicableUs
VasopressinInjection, solution20 [USP'U]/mLIntramuscular; SubcutaneousGeneral Injectables & Vaccines2010-08-012017-01-20Us
VasopressinInjection, solution20 [USP'U]/mLIntramuscular; SubcutaneousAmerican Regent1992-10-01Not applicableUs
VasopressinInjection, solution20 [USP'U]/mLIntramuscular; SubcutaneousGeneral Injectables & Vaccines2010-03-012017-01-20Us
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIIY87Y826H08
CAS number11000-17-2
Pharmacology
IndicationFor the treatment of enuresis, polyuria, diabetes insipidus, polydipsia and oesophageal varices with bleeding
Structured Indications
PharmacodynamicsVasopressin is an antidiuretic hormone indicated for the prevention and treatment of postoperative abdominal distention, in abdominal roentgenography to dispel interfering gas shadows, and in diabetes insipidus. Vasopressin can cause contraction of smooth muscle of the gastrointestinal tract and of all parts of the vascular bed, especially the capillaries, small arterioles and venules. It has less effect on the smooth musculature of the large veins. Vasopressin may also be used to control bleeding in some forms of von Willebrand disease and to treat extreme cases of bed wetting in children. It may also play a role in memory formation although the mechanism is unknown.
Mechanism of actionVasopressin acts on three different receptors, vasopressin receptor V1a (which initiates vasoconstriction, liver gluconeogenesis, platelet aggregation and release of factor VIII), vasopressin receptor V1b (which mediates corticotrophin secretion from the pituitary) and vasopressin receptor V2 which controls free water reabsorption in the renal medullar. The binding of vasopressin to the V2 receptor activates adenylate cyclase which causes the release of aquaporin 2 channels into the cells lining the renal medullar duct. This allows water to be reabsorbed down an osmotic gradient so the urine is more concentrated.
TargetKindPharmacological actionActionsOrganismUniProt ID
Vasopressin V2 receptorProteinyes
agonist
HumanP30518 details
Vasopressin V1a receptorProteinyesNot AvailableHumanP37288 details
Vasopressin V1b receptorProteinyesNot AvailableHumanP47901 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding1%
Metabolism

The majority of a dose of vasopressin is metabolized and rapidly destroyed in the liver and kidneys.

Route of eliminationNot Available
Half life10-20 minutes
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions No interactions found.
Food Interactions
  • Ethanol
References
Synthesis Reference

Nedumparambil A. Abraham, Hans U. Immer, Kazimir Sestanj, “Process for producing triglycyl-lysine vasopressin and intermediates therefor.” U.S. Patent US4093610, issued June, 1963.

US4093610
General References
  1. Bielsky IF, Hu SB, Szegda KL, Westphal H, Young LJ: Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. Neuropsychopharmacology. 2004 Mar;29(3):483-93. [PubMed:14647484 ]
  2. Wersinger SR, Caldwell HK, Martinez L, Gold P, Hu SB, Young WS 3rd: Vasopressin 1a receptor knockout mice have a subtle olfactory deficit but normal aggression. Genes Brain Behav. 2007 Aug;6(6):540-51. Epub 2006 Nov 3. [PubMed:17083331 ]
  3. Lolait SJ, Stewart LQ, Jessop DS, Young WS 3rd, O'Carroll AM: The hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors. Endocrinology. 2007 Feb;148(2):849-56. Epub 2006 Nov 22. [PubMed:17122081 ]
  4. Wersinger SR, Kelliher KR, Zufall F, Lolait SJ, O'Carroll AM, Young WS 3rd: Social motivation is reduced in vasopressin 1b receptor null mice despite normal performance in an olfactory discrimination task. Horm Behav. 2004 Dec;46(5):638-45. [PubMed:15555506 ]
  5. Kanwar S, Woodman RC, Poon MC, Murohara T, Lefer AM, Davenpeck KL, Kubes P: Desmopressin induces endothelial P-selectin expression and leukocyte rolling in postcapillary venules. Blood. 1995 Oct 1;86(7):2760-6. [PubMed:7545469 ]
External Links
ATC CodesH01BA06H01BA01
AHFS Codes
  • 68:28.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (143 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic SciencePsychology, Social1
0RecruitingBasic SciencePsychology, Social1
1CompletedDiagnosticAutism Spectrum Disorder (ASD)1
1Unknown StatusTreatmentCardiac Arrest / Cardiopulmonary Arrest1
2CompletedTreatmentAcute Lung Injury (ALI)1
2CompletedTreatmentHeart Arrest1
2CompletedTreatmentShock, Septic1
2RecruitingTreatmentAutism Spectrum Disorder (ASD)1
2RecruitingTreatmentEnd Stage Renal Disease (ESRD) / Hypertensive1
2RecruitingTreatmentTraumatic Shock1
2TerminatedTreatmentPulmonary Hypertension (PH)1
2Unknown StatusBasic ScienceHealthy Volunteers1
2, 3CompletedTreatmentHypovolaemia / Shock / Shock, Hemorrhagic1
2, 3CompletedTreatmentSepsis / Shock, Septic1
2, 3CompletedTreatmentShock, Septic1
2, 3RecruitingTreatmentCirculatory Perfusion Disorder / Congenital Heart Disease (CHD) / Single-ventricle1
2, 3RecruitingTreatmentPleural Effusions / Single-ventricle1
3Active Not RecruitingTreatmentShock, Septic1
3CompletedTreatmentCardiac Arrest2
3CompletedTreatmentUterine Myomas1
3Unknown StatusTreatmentShock1
4Active Not RecruitingTreatmentShock, Septic1
4CompletedBasic ScienceEndotoxaemia1
4CompletedPreventionHemorrhage1
4CompletedPreventionKidney Failure1
4CompletedTreatmentBlood Loss During Vaginal Hysterectomy1
4CompletedTreatmentBlood Loss,Surgical1
4RecruitingTreatmentShock1
Not AvailableCompletedNot AvailableRotator Cuff Tear Arthropathy1
Not AvailableCompletedBasic ScienceHealthy Volunteers2
Not AvailableCompletedDiagnosticShock, Septic1
Not AvailableCompletedTreatmentHypotension1
Not AvailableCompletedTreatmentTraumatic Brain Injury (TBI)1
Not AvailableEnrolling by InvitationBasic ScienceHepatic Hemodynamics / Liver Surgery / Portal Blood Pressure1
Not AvailableNot Yet RecruitingBasic ScienceHealthy Volunteers1
Not AvailableNot Yet RecruitingPreventionMyomas1
Not AvailableRecruitingPreventionHypotension1
Not AvailableTerminatedSupportive CareShock, Septic1
Not AvailableTerminatedTreatmentInjury / Traumatic Shock1
Not AvailableUnknown StatusBasic ScienceHealthy Volunteers1
Not AvailableUnknown StatusTreatmentLiver Failure1
Pharmacoeconomics
Manufacturers
  • Parke davis div warner lambert co
Packagers
Dosage forms
FormRouteStrength
InjectionIntramuscular; Subcutaneous20 [USP'U]/mL
LiquidIntramuscular; Subcutaneous10 unit
InjectionIntramuscular20 [USP'U]/mL
Injection, solutionIntramuscular; Subcutaneous20 [USP'U]/mL
LiquidIntramuscular; Nasal; Subcutaneous20 unit
LiquidIntramuscular; Subcutaneous20 unit
SolutionIntramuscular; Subcutaneous20 unit
InjectionIntravenous20 [USP'U]/mL
Prices
Unit descriptionCostUnit
Pitressin 20 unit/ml vial7.68USD ml
Vasopressin 10 unit/0.5 ml vial2.88USD vial
Vasopressin 20 unit/ml vial1.86USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySolubleNot Available
hydrophobicity-4.9Not Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Vasopressin receptor activity
Specific Function:
Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Involved in renal water reabsorption.
Gene Name:
AVPR2
Uniprot ID:
P30518
Molecular Weight:
40278.57 Da
References
  1. Boson WL, Della Manna T, Damiani D, Miranda DM, Gadelha MR, Liberman B, Correa H, Romano-Silva MA, Friedman E, Silva FF, Ribeiro PA, De Marco L: Novel vasopressin type 2 (AVPR2) gene mutations in Brazilian nephrogenic diabetes insipidus patients. Genet Test. 2006 Fall;10(3):157-62. [PubMed:17020465 ]
  2. Slusarz MJ, Slusarz R, Ciarkowski J: Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system. Biopolymers. 2006 Apr 5;81(5):321-38. [PubMed:16333859 ]
  3. Bouley R, Hawthorn G, Russo LM, Lin HY, Ausiello DA, Brown D: Aquaporin 2 (AQP2) and vasopressin type 2 receptor (V2R) endocytosis in kidney epithelial cells: AQP2 is located in 'endocytosis-resistant' membrane domains after vasopressin treatment. Biol Cell. 2006 Apr;98(4):215-32. [PubMed:16563128 ]
  4. Yi X, Bouley R, Lin HY, Bechoua S, Sun TX, Del Re E, Shioda T, Raychowdhury MK, Lu HA, Abou-Samra AB, Brown D, Ausiello DA: Alix (AIP1) is a vasopressin receptor (V2R)-interacting protein that increases lysosomal degradation of the V2R. Am J Physiol Renal Physiol. 2007 May;292(5):F1303-13. Epub 2007 Feb 6. [PubMed:17287200 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Vasopressin receptor activity
Specific Function:
Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system. Has been involved in social behaviors, including affiliation and attachment.
Gene Name:
AVPR1A
Uniprot ID:
P37288
Molecular Weight:
46799.105 Da
References
  1. Hiroyama M, Wang S, Aoyagi T, Oikawa R, Sanbe A, Takeo S, Tanoue A: Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice. Eur J Pharmacol. 2007 Mar 22;559(2-3):89-97. Epub 2006 Dec 29. [PubMed:17275806 ]
  2. Liedman R, Grant L, Igidbashian S, James I, McLeod A, Skillern L, Akerlund M: Intrauterine pressure, ischemia markers, and experienced pain during administration of a vasopressin V1a receptor antagonist in spontaneous and vasopressin-induced dysmenorrhea. Acta Obstet Gynecol Scand. 2006;85(2):207-11. [PubMed:16532916 ]
  3. Adikesavan NV, Mahmood SS, Stanley N, Xu Z, Wu N, Thibonnier M, Shoham M: A C-terminal segment of the V1R vasopressin receptor is unstructured in the crystal structure of its chimera with the maltose-binding protein. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2005 Apr 1;61(Pt 4):341-5. Epub 2005 Mar 24. [PubMed:16511036 ]
  4. Hammock EA, Lim MM, Nair HP, Young LJ: Association of vasopressin 1a receptor levels with a regulatory microsatellite and behavior. Genes Brain Behav. 2005 Jul;4(5):289-301. [PubMed:16011575 ]
  5. Aoyagi T, Birumachi J, Hiroyama M, Fujiwara Y, Sanbe A, Yamauchi J, Tanoue A: Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology. 2007 May;148(5):2075-84. Epub 2007 Feb 15. [PubMed:17303660 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Vasopressin receptor activity
Specific Function:
Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system.
Gene Name:
AVPR1B
Uniprot ID:
P47901
Molecular Weight:
46970.345 Da
References
  1. Young WS, Li J, Wersinger SR, Palkovits M: The vasopressin 1b receptor is prominent in the hippocampal area CA2 where it is unaffected by restraint stress or adrenalectomy. Neuroscience. 2006 Dec 28;143(4):1031-9. Epub 2006 Oct 4. [PubMed:17027167 ]
  2. Volpi S, Liu Y, Aguilera G: Vasopressin increases GAGA binding activity to the V1b receptor promoter through transactivation of the MAP kinase pathway. J Mol Endocrinol. 2006 Jun;36(3):581-90. [PubMed:16720725 ]
  3. Wersinger SR, Caldwell HK, Christiansen M, Young WS 3rd: Disruption of the vasopressin 1b receptor gene impairs the attack component of aggressive behavior in mice. Genes Brain Behav. 2007 Oct;6(7):653-60. Epub 2006 Dec 20. [PubMed:17284170 ]
  4. Slusarz MJ, Gieldon A, Slusarz R, Ciarkowski J: Analysis of interactions responsible for vasopressin binding to human neurohypophyseal hormone receptors-molecular dynamics study of the activated receptor-vasopressin-G(alpha) systems. J Pept Sci. 2006 Mar;12(3):180-9. [PubMed:16114100 ]
  5. Jurkevich A, Berghman LR, Cornett LE, Kuenzel WJ: Characterization and immunohistochemical visualization of the vasotocin VT2 receptor in the pituitary gland of the chicken, Gallus gallus. Gen Comp Endocrinol. 2005 Aug;143(1):82-91. Epub 2005 Mar 23. [PubMed:15993108 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Madon J, Hagenbuch B, Landmann L, Meier PJ, Stieger B: Transport function and hepatocellular localization of mrp6 in rat liver. Mol Pharmacol. 2000 Mar;57(3):634-41. [PubMed:10692506 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23